Scholars Central

Research articlePublished 2015

Landscape and Targeting of the Angpt-Tie System in Current Anticancer Therapy

Authors: LYu Sun, Boyi Zhang

Translational Medicine

Volume 5 · Issue 4 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Strategies using angiogenesis inhibitors to suppress tumor development via interfering with vascular signaling have been explored for more than a decade. To date, anti-angiogenenic agents such as bevacizumab, sorafenib and sunitinib are incorporated into standard administration to treat many cancer types by targeting the vascular endothelial growth factor A (VEGFA) pathway. However, only mild and transient responses were observed in most cases, raising the topic of drug resistance as one of the major problems that is frequently encountered by clinicians. The angiopoietin (Angpt)-Tie system, previously considered as a second line pathway in tumor angiogenic switch that functionally contributes to angiogenesis and/or lymphangiogenesis, recently attracted substantial interest and is entering the spotlight for meticulous studies in cancer biology. Agents specifically suppressing Angpts are now in clinical trials, and new reports suggest promising anti-cancer activities with a safety profile distinct from those of anti- VEGFA therapeutics. This review provides an updated picture of the Angpt-Tie system, by focusing on the Angpt-Tie2 axis in basic research and clinical investigation, and discusses feasible options to therapeutically target this signaling pathway in the context of precision medicine.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Translational Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTranslational Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “LYu Sun”
  • BylineArticles whose byline prints “Boyi Zhang”